Back
03/05/18

Aquinox Pharmaceuticals to Announce Year End 2017 Financial Results

Conference call Monday March 12, 2018 at 4:30 PM ET

VANCOUVER, British Columbia, March 05, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, will report its financial results for the year ending December 31, 2017 and will provide a general business update on Monday March 12, 2018 after U.S. markets close.

Conference Call and Webcast Details:
Date: Monday March 12, 2018
Time: 4:30 PM (ET) / 1:30 PM (PT)
Toll-free: (866) 357-7878
International: (315) 625-3088
Audience Passcode 4665267
Webcast URL: https://edge.media-server.com/m6/p/9vvkbdes

The live webcast may be accessed through the "Events & Presentations" page in the "Investor Relations" section of the company's website at www.aqxpharma.com. The archived webcast will also be available on Aquinox's website approximately two hours after the event and will be available for replay for at least 30 days after the event.

AboutAquinoxPharmaceuticals, Inc.

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics for chronic urological conditions marked by inflammation and pain. Aquinox's lead drug candidate, rosiptor (AQX-1125), is a first-in-class, once-daily, oral treatment with a novel mechanism of action, activating SHIP1 (SH2-containing inositol-5'-phosphatase 1), an enzyme that serves to down-regulate inflammation through its role in the PI3K signaling pathway. Rosiptor is in Phase 3 development for the treatment of patients with interstitial cystitis/bladder pain syndrome (IC/BPS), a debilitating condition marked by chronic bladder pain and urinary symptoms, for which there are currently few FDA approved and/or effective treatment options. Aquinox is focused on leveraging its library of novel compounds that activate SHIP1 to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. For more information, please visit www.aqxpharma.com.

Contact Info:

Brendan Payne
Associate Director, Investor Relations 
Aquinox Pharmaceuticals, Inc.
604.901.3019
ir@aqxpharma.com
Bill Kadel
Vice President
Solebury Trout
646.378.2934
bkadel@troutgroup.com 

Primary Logo

 

Source: Aquinox Pharmaceuticals, Inc.